ASX Announcement

27 June 2022
Minneapolis USA

AGREEMENTS SIGNED WITH SIEMENS ENABLE IMRICOR 3D MAPPING SYSTEM AND BUSINESS UPDATE

Highlights

- **Siemens Agreements provides Imricor the ability to deploy the upcoming Imricor 3D mapping system across all newer Siemens MRI scanners**
- **Prototype versions of the Imricor 3D mapping system will be evaluated at certain sites in Q3**
- **Imricor's 3D mapping system is expected to allow Siemens iCMR sites to participate in the planned VT clinical trial**
- **Preclinical studies to support a submission for approval to begin the VT clinical trial have been completed**
- **Procedures have re-commenced at the Haga Teaching Hospital**

Imricor Medical Systems, Inc. (**Company** or **Imricor**) (**ASX:IMR**), the global leader in realtime iCMR cardiac ablation products, is pleased to announce it has entered into two new agreements with Siemens Healthcare GmbH (Siemens) that together provide Imricor the ability to deploy the Company's new 3D mapping system on the Siemens MRI platform.

The objectives behind Imricor developing its own 3D mapping system, combined with the Siemens agreements announced here, are to commercialise a 3D mapping system for the Siemens platform sooner than previously possible and to provide Siemens iCMR sites an opportunity to participate in Imricor's planned ventricular tachycardia ablation (VT) clinical trial.

Siemens Agreements

The first agreement is an Access-i License Agreement which provides Imricor the ability to interface Imricor's new 3D mapping system to Siemens MRI scanners via the Access-i software interface available on newer Siemens scanners, including the Aera, Altea, and Sola systems. Access-i is a CE mark certified software product available today from Siemens.

The second agreement is a Local Coil Agreement which allows Imricor catheters to be recognised across newer Siemens MRI scanners, including the Aera, Altea, and Sola systems.

Both agreements have an initial term ending 31 December 2026 and shall be automatically extended by periods of 12 months thereafter, unless terminated by either party.

Imricor's Chair and CEO, Steve Wedan, commented: "This is extremely significant to our business. We began developing our own 3D mapping system in January with the intent to

remove our reliance on third parties with respect to delivering such a mapping system, and our development, in close collaboration with Siemens, continues to exceed our expectations.



Screenshot of Imricor's Prototype 3D Mapping System on a Siemens Aera 1.5T MRI

"With the completion of the Access-i License Agreement and the Local Coil Agreement, we now have full control (within normal regulatory boundaries) over the deployment of our 3D mapping system to our customers who have Siemens' Aera or newer systems. Early prototype versions of the 3D mapping systems will be used, starting in Q3, for research and clinical trial purposes, including our upcoming VT trial, with the end goal of CE mark certification for the 3D mapping system at the same time we receive VT indications for our second-generation Vision-MR Ablation Catheter.

"The entire 3D mapping system program is a result of the close partnership we have with Siemens, and we are very pleased with how our partnership continues to grow and mature."

Ventricular Tachycardia Update

The Company has completed its preclinical work to support a submission for approval to initiate a VT clinical trial in Europe. The purpose of preclinical studies is to demonstrate the safe use and expected functionality of all the devices needed to perform a VT ablation procedure. These devices include Imricor's Advantage-MR EP Recorder/Stimulator, Vision-MR Ablation Catheter (second generation), Vision-MR Diagnostic Catheter, Vision-MR Dispersive Electrode, NavTrac-MR Transseptal Puncture Kit (including a steerable sheath, transseptal needle, and actively tracked dilator), as well as third-party devices such as the Osypka HAT500 Ablation Generator, MiRTLE Medical's 12-lead ECG, and MIPM's prototype defibrillator.

Imricor's Chair and CEO, Steve Wedan, noted: "We are one step closer, as planned, to VT ablations performed with realtime iCMR guidance, and we couldn't be more thrilled. Complex ablation procedures, like VT, are the ones for which we believe MR imaging will add great value

to patients, physicians, hospitals, and payers. These are the types of procedures that motivated me to start Imricor in the first place. As we approach the beginning of VT ablations in the iCMR lab, we are witnessing the culmination of a decade and a half of dedication to our mission: to improve patient care and save lives by delivering state-of-the-art MR imaging capabilities to interventional medicine."

Procedures Commencing

As the pandemic effects wane, atrial flutter ablation procedures using Imricor's products continue to commence across the Company's contracted sites. Most recently, the Haga Teaching Hospital in The Hague started performing procedures again in June. Cases are also expected to re-commence at the Amsterdam University Medical Center following final MRI upgrades being performed this week.

In addition, installations are complete at Policlinico Casilino in Rome and Henry Dunant Hospital Center in Athens. Cases will commence at these sites once the Osypka HAT500 ablation generator is registered in those countries, a process that is expected to be completed very soon.

ENDS

Authorised for release by Steve Wedan, Executive Chair, President, and CEO.

Further Information

Investors:
Steve Wedan
Executive Chair, President and CEO
Email: steve.wedan@imricor.com

Investors & Australian Media:
Simon Hinsley
Executive Director, NWR Communications
Email: simon@nwrcommunications.com.au
Mobile: +61 (0) 401 809 653

Rest of World Media:
Nick Twohy
Vice President of Marketing, Imricor
Email: nick.twohy@imricor.com
Phone: +1 952 818 8407

About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is a leading developer of innovative MRI-compatible medical devices which can be used to carry out MRI-guided cardiac catheter ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac catheter ablation procedures.

Imricor's Products

Imricor is a pioneer and leader in developing MRI-compatible products for cardiac catheter ablation procedures, and believes it is the first company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market.

The Vision-MR Ablation Catheter is the Company's prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters. The Vision-MR Ablation Catheter has been approved in the European Union with an indication for treating type 1 atrial flutter. Imricor intends to seek approval for expanded indications in the future. The Company is also in the early stages of pursuing the required regulatory approvals to place its key products on the market in Australia and the U.S.

The Company has also obtained approval within the EU for the sale of the Advantage-MR EP Recorder/Stimulator System and its consumable product, the Vision-MR Dispersive Electrode.

Imricor sells its capital and consumable products to hospitals and clinics for use in Interventional Cardiac Magnetic Resonance Imaging (iCMR) labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed. An iCMR lab is an interventional lab that is fitted with MRI equipment for use in cardiac diagnostic and interventional procedures. The installation of iCMR labs is driven primarily by MRI equipment vendors working collaboratively with Imricor. Vendors such as Koninklijke Philips N.V. and Siemens Healthcare GmbH help to target certain sites and support the design and construction of iCMR labs for those sites.

Foreign Ownership Restrictions

Imricor's CHESS Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU. sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.